There are considerable physiological, clinical and genetic data that point to the kidney as the major regulator of blood pressure and to renal damage as a consequence of long-term blood pressure elevation. However, alternative hypotheses, such as increased systemic vascular resistance, are also serious contenders to explain the rise of blood pressure with increasing age, but these hypotheses currently have limited genetic support. The genetic basis of elevated blood pressure, or hypertension (HTN), involves many loci that have been identified using largescale analyses of candidate genes 1,2 , linkage studies and genome-wide association studies (GWAS) 3-12 . Identification of the genes underlying blood pressure regulation can help resolve many of the open questions regarding blood pressure (patho)physiology. Although ~40-50% of variability in blood pressure is heritable 13,14 , the associated genetic variation identified thus far explains only ~2% (refs. 1-12).
To dissect the genetic architecture of blood pressure and assess effects on target organ damage, we analyzed 128,272 SNPs from targeted and genome-wide arrays in 201,529 individuals of European ancestry, and genotypes from an additional 140,886 individuals were used for validation. We identified 66 blood pressure-associated loci, of which 17 were new; 15 harbored multiple distinct association signals. The 66 index SNPs were enriched for cis-regulatory elements, particularly in vascular endothelial cells, consistent with a primary role in blood pressure control through modulation of vascular tone across multiple tissues. The 66 index SNPs combined in a risk score showed comparable effects in 64,421 individuals of non-European descent. The 66-SNP blood pressure risk score was significantly associated with target organ damage in multiple tissues but with minor effects in the kidney. Our findings expand current knowledge of blood pressure-related pathways and highlight tissues beyond the classical renal system in blood pressure regulation.
with genome-wide genotyping data had contributed to previous analyses (Supplementary Tables 1-3 ) 5, 7 .
Blood pressure was measured using standardized protocols in all studies 5, 17 (Online Methods and Supplementary Table 1 ). Association statistics for systolic and diastolic blood pressure (SBP and DBP) in models adjusting for age, age 2 , sex and body mass index (BMI) were obtained for each study separately, with study-specific genomic control applied to correct for possible population structure. Fixed-effects metaanalysis was carried out in four stages, separately for the following SNP associations: stage 1, meta-analysis using results based on 46 studies with Cardio-MetaboChip genotypes of 109,096 participants; stage 2, meta-analysis using additional results based on imputed genotypes from genome-wide genotyping arrays in 4 previously unpublished studies; stage 3, meta-analysis using imputed genotypes from genomewide genotyping arrays in 24 previously published studies 5 ; and stage 4, joint meta-analysis of stages 1-3 including a total of 201,529 independent individuals ( Supplementary Fig. 1, Supplementary Tables 2 and 3 , and Supplementary Note). To account for population structure across studies in stages 1-3 of our meta-analysis, genomic control correction was applied to meta-analysis results from each of these stages considered independently 18, 19 . Association statistics (P values) are available as Supplementary Data, and full association results are available via the database of Genotypes and Phenotypes (dbGaP) (phs000585.v2.p1).
After stage 4, 67 loci attained genome-wide significance (P < 5 × 10 −8 ), 18 of which were not previously reported in the literature ( Supplementary Table 4 ). Quantile-quantile plots of the stage 4 metaanalysis showed an excess of small P values, with an elevated genomic control λ estimate that was persistent, albeit attenuated, after excluding all 66 loci (Supplementary Fig. 2) . This observation is compatible with either residual uncorrected population stratification or the presence of a large number of variants that are truly associated with blood pressure but fail to achieve genome-wide significance in the current meta-analysis. The Cardio-MetaboChip array's inclusion of SNPs 1 1 7 2 VOLUME 48 | NUMBER 10 | OCTOBER 2016 Nature GeNetics A r t i c l e s from an earlier blood pressure GWAS 5 does not seem to be the sole explanation, as we did not observe a significant decrease in the excess of small P values after exclusion of all SNPs that were included on the Cardio-MetaboChip because of nominal association with blood pressure ( Supplementary Figs. 3 and 4) . Because the quantile-quantile plots continued to show deviation from the null expectation, we sought additional validation for 18 variants attaining genome-wide significance but without previous support in the literature in up to 140,886 individuals of European ancestry from UK Biobank 20 . For these SNPs, we performed a stage 5 meta-analysis combining the association summary statistics from stage 4 and UK Biobank, in a total of up to 342,415 individuals ( Supplementary Table 5 ).
After stage 5 meta-analysis, 17 of 18 variants retained genome-wide significance for the primary trait (SBP or DBP result with the lower P value). The one variant that was not genome-wide significant had a borderline P value of 4.49 × 10 −8 in stage 4. These findings are consistent with appropriate calibration of the association test statistics at stage 4 in that observing one failure among 18 validation tests is consistent with the use of a significance threshold (P < 5 × 10 −8 ) designed to have a 1 in 20 chance of yielding a result as or more extreme than one solely due to chance. In total, 66 loci attained genome-wide significance: 13 loci for SBP only, 12 loci for DBP only and 41 loci for both traits. Of these, 17 blood pressure loci were new, whereas 49 were previously reported at genome-wide significance ( Fig. 1 and Table 1 ).
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A r t i c l e s
As expected from the high correlation between effects on SBP and DBP, the observed directions of effect for the two traits were generally concordant ( Supplementary Fig. 5 ). The absolute effect sizes were inversely correlated with MAF ( Table 1 and Supplementary Fig. 6 ).
The 66 blood pressure-associated SNPs explained 3.46% and 3.36% of variance in SBP and DBP, respectively, a modest increase from the 2.95% and 2.78% explained by the 49 previously reported SNPs (Supplementary Note). The low percentage variance explained is consistent with estimates that large numbers of common variants with weak effects at a large number of loci influence blood pressure 5 .
Signal refinement at the 66 blood pressure loci
To identify distinct signals of association at the 66 blood pressure loci and the variants most likely to be causal for each, we started with an approximate conditional analysis using a model selection procedure implemented in the GCTA-COJO package 22, 23 as well as a detailed literature review of all published blood pressure association studies. GCTA-COJO analysis was performed using the association summary statistics for SBP and DBP from the stage 4 EUR-ancestry meta-analyses, with linkage disequilibrium (LD) between variants estimated on the basis of Cardio-MetaboChip genotype data from 7,006 individuals of EUR ancestry from the GoDARTS cohort 24 . More than one distinct blood pressure association signal was identified for 13 loci at P < 5 × 10 −8 ( Supplementary Fig. 7 , Supplementary Table 6 and Supplementary Note). At six loci, the distinct signals were identified for SBP and DBP when these traits were analyzed separately; these trait-specific associations were represented by the same or highly correlated (r 2 >0.8) SNPs at five of the six loci ( Supplementary Tables 7  and 8 ). We repeated GCTA-COJO analyses using the same summary association results but with a different reference sample for LD estimates (WTCCC1-T2D/58BC, n = 2,947; Supplementary Note) and observed minimal differences arising from minor fluctuations in the association P value in the joint regression models ( Supplementary  Tables 7 and 8 ). LD-based comparisons of published association signals at established blood pressure loci and the current study's findings suggested that, at ten loci, the signals identified by the single-SNP and GCTA-COJO analyses were distinct from those reported in the literature ( Supplementary Table 9 ). We then performed multivariate regression modeling in a single large cohort (Women's Genome Health Study, WGHS; n = 23,047) with simultaneous adjustment for (i) all combinations of putative index SNPs for each distinct signal from the GCTA-COJO conditional analyses and (ii) all index SNPs for all potential distinct signals identified by our literature review ( Supplementary Table 9 and Supplementary Note). Although WGHS is very large as a single study, power is lower in a single sample than in the overall meta-analysis (23,000 versus 342,000 individuals) and, consequently, the failure to reach significance does not represent non-replication for individual SNPs. The WGHS analysis supported two distinct association signals at 8 of the 13 loci identified in the GCTA-COJO analysis but could not provide npg support for the remaining 5 (Supplementary Table 10 ). The joint SNP modeling in WGHS additionally supported two distinct signals of association at three other loci (GUCY1A3-GUCY1B3, SYNPO2L and TBX5-TBX3) at which the SNP identified in the current study is distinct from that previously reported in the literature 5, 11 . We sought to refine the localization of likely functional variants in loci with high-density coverage on the Cardio-MetaboChip. We followed a Bayesian approach to define, for each signal, credible sets of variants that had 99% probability of containing or tagging the causal variant (Supplementary Note). To improve the resolution of the method, the analyses were restricted to 24 regions selected to fine-map genetic associations and that included at least one SNP reaching genome-wide significance in the current meta-analyses ( Supplementary Table 11 ). Twenty-one of the Cardio-MetaboChip fine-mapped regions were designated blood pressure loci in the original design, and three of the newly discovered blood pressure loci corresponded to fine-mapped regions originally selected for other, non-blood pressure traits. We observed that the 99% credible SNP sets at five blood pressure loci spanned <20 kb. The greatest refinement was observed at the SLC39A8 locus for SBP and DBP and at the ZC3HC1 and PLCE1 loci for DBP, where the 99% credible sets included only the index variants ( Supplementary Table 12 ). Although SNPs in credible sets were primarily noncoding, they included one synonymous and seven nonsynonymous variants that attained high posterior probability of driving seven distinct association signals in six blood pressure loci ( Supplementary Table 12 ). Of these, three variants by themselves accounted for more than 95% of the posterior probability of driving the association signal observed at each of three loci (Supplementary Tables 12 and 13) . Despite reduced statistical power, the analyses restricted to only the samples with Cardio-MetaboChip genotypes (n = 109,096) identified the majority of SNPs identified in the GWAS + Cardio-MetaboChip data ( Supplementary  Table 12 ). The full lists of SNPs in the 99% credible sets are given in Supplementary Table 13 .
Functional annotation of blood pressure variants
Index SNPs or their proxies (r 2 >0.8) altered amino acid sequence at 11 of 66 blood pressure loci ( Table 1) . Thus, the majority of blood pressure association signals are likely driven by noncoding variants hypothesized to regulate expression of some nearby gene in cis. To characterize their effects, we first sought SNPs associated with gene expression (eSNPs) from a range of available expression data that included HTN target end organs and cells of the circulatory system (heart tissue, kidney tissue, brain tissue, aortic endothelial cells and blood vessels) as well as other tissue and cell types (CD4 + macrophages, monocytes, lymphoblastoid cell lines, skin tissue, fat tissue and liver tissue). Fourteen blood pressure-associated SNPs at the MTHFR-NPPB, MDM4, ULK4, CYP1A1-ULK3, ADM, FURIN-FES, FIGN and PSMD5 loci were eSNPs across different tissues ( Supplementary  Table 14 ). Of these 14 eSNPs, 3 were also predicted to alter amino acid sequence at the MTHFR-NPPB, MAP4 and ULK4 loci, providing two potential mechanisms to explore in functional studies. Second, we used gene expression levels measured in whole blood in two different samples each including >5,000 individuals of EUR descent. We tested whether the lead blood pressure SNP was associated with expression of any transcript in cis (<1 Mb from the lead SNP at each locus) at a false discovery rate (FDR) of <0.05, accounting for all possible cis transcript association tests across the genome. It is likely that we did not genotype the causal genetic variant underlying each blood pressure association signal; a nearby SNP-transcript association, identified by LD, may therefore reflect an independent genetic effect on expression that is unrelated to the effect on blood pressure. Consequently, we required that the lead blood pressure SNP and the most significant eSNP for a given transcript be highly correlated (r 2 >0.7). Furthermore, we required that the significance of the transcript association with the lead blood pressure SNP be substantially reduced in a conditional model adjusting for the best eSNP for a given transcript. Eighteen SNPs at 15 loci were associated with 22 different transcripts, with a total of 23 independent SNP-transcript associations (3 SNPs were associated with 2 transcripts each; Supplementary Table 15 and Supplementary Note). The genes expressed in an allele-specific manner with respect to blood pressure SNPs are clearly high-priority candidates to mediate the association with blood pressure. In whole blood, these genes included obvious biological candidates such as GUCY1A3, encoding the α subunit of the soluble guanylate cyclase protein, and ADM, encoding adrenomedullin, both of which are known to induce vasodilation 25, 26 . There was some overlap of eSNPs between the whole blood and other tissue data sets at the MTHFR-NPPB, MDM4, PSMD5, ULK4 and CYP1A1-ULK3 loci.
An alternative method to prioritize noncoding variants at blood pressure loci that are most likely to be causal is to determine whether they fall within DNase I hypersensitivity sites (DHSs). We performed two analyses to investigate whether blood pressure SNPs or their LD proxies (r 2 >0.8) were enriched in DHSs in a cell-type-specific manner (Supplementary Note). First, we used Epigenomics Roadmap and Encyclopedia of DNA Elements (ENCODE) DHS data from 123 cell lines or tissues derived from adults [27] [28] [29] to estimate the fold increase in the proportion of blood pressure SNPs mapping to DHSs as compared to SNPs associated at genome-wide significance with non-blood pressure phenotypes from the National Human Genome Research Institute (NHGRI) GWAS catalog 30 . We observed that 7 of the 10 cell types with the greatest relative enrichment of blood pressure SNPs mapping to DHSs were from blood vessels (vascular or microvascular endothelial cell lines or cells), and 11 of the 12 endothelial cell types were among the top 25% most enriched among the 123 cell types ( Fig. 2  and Supplementary Table 16 ). In a second analysis of an expanded set of tissues and cell lines, in which cell types were grouped into tissues ( Supplementary Table 17 ), blood pressure-associated SNP enrichment in DHSs in blood vessels was again observed (P = 1.2 × 10 −9 ), as well as in heart samples (P = 5.3 × 10 −8 ; Supplementary Table 18 ).
We next tested whether there was enrichment of blood pressure SNPs among sites with trimethylation of histone H3 at lysine 4 (H3K4me3) 31 , a methylation mark associated with both promoters and enhancers. We observed significant enrichment in a range of cell types including CD34 + primary cells, adult kidney cells and muscle satellite cultured cells ( Supplementary Table 19 ). Enrichment of blood pressure SNPs in regions with predicted strong and weak enhancer A r t i c l e s states and in active promoters 32 in a range of cell types was also observed ( Supplementary Fig. 8 and Supplementary Table 20 ). We used Meta-Analysis Gene Set Enrichment of Variant Associations (MAGENTA) 33 to attempt to identify pathways overrepresented in the blood pressure association results. No gene sets meeting experiment-wide significance for enrichment for blood pressure association were identified by MAGENTA after correction for multiple testing, although some attained nominal significance ( Supplementary Table 21 and Supplementary Note). We also adapted the Data-Driven Expression Prioritized Integration for Complex Traits (DEPICT) 34 pathway analysis tool to identify assembled gene sets that were enriched for genes near associated variants and to assess whether genes from associated loci were highly expressed in particular tissues or cell types. Using the extended blood pressure locus list based on genome-wide significant loci from this analysis and previously published SNPs that might not have reached genome-wide significance in the current analysis ( Supplementary  Table 9 ), we identified five significant (FDR 5%) gene sets: abnormal cardiovascular system physiology, G α12,13 signaling events, embryonic growth retardation, prolonged QT interval and abnormal vitelline vasculature morphology. We also found that suggestive SBP and DBP associations (P < 1 × 10 −5 ) were enriched for reconstituted gene sets at DBP loci (mainly related to developmental pathways) but not at SBP loci ( Supplementary Table 22 and Supplementary Note). In a final analysis, we assessed Cardio-MetaboChip SNPs at the fine-mapping loci using formaldehyde-assisted isolation of regulatory elements (FAIRE-gen) in lymphoblastoid cell lines 35 . Our results provided support for two SNPs, one of which (rs7961796 in the TBX5-TBX3 locus) was located in a regulatory site. Although the other SNP (rs3184504 in the SH2B3 locus) is a nonsynonymous variant, there was also a regulatory site indicated by DNase I and monomethylation at histone H3 at lysine 4 (H3K4me1) signatures at the locus, making the SNP a potential regulatory variant ( Supplementary Table 23 ) 36 . Both SNPs were included in the list of 99% credible SNPs at each locus.
Asian- and African-ancestry blood pressure SNP association
We tested the 66 lead SNPs at the established and new loci for association with blood pressure in up to 20,875 individuals of South Asian (SAS) ancestry (PROMIS and RACE studies), 9,637 individuals of East Asian (EAS) ancestry (HEXA, HALST, CLHNS, DRAGON and TUDR studies) and 33,909 individuals of African (AFR) ancestry (COGENT-BP Consortium, Jupiter, SPT, Seychelles, GXE and TANDEM studies). As expected, effect allele frequencies were very similar across studies of the same ancestry group but were markedly different across different ancestry groups (Supplementary Fig. 9 ). Many associations for individual SNPs failed to reach P < 0.05 for the blood pressure trait with the lower P value ( Supplementary Table 24 ), which could potentially be because of the much lower statistical power at the sample sizes available, different patterns of LD at each locus across ancestry groups, variability in allele frequency or true lack of association in individuals of a given non-European ancestry. The low statistical power for the great majority of SNPs tested was apparent when considering SNP-by-SNP power calculations using Europeanancestry effect sizes ( Supplementary Table 24 ). However, concordant directions of allelic effect for both SBP and DBP were observed for 45 of 66 SNPs in SAS samples, 36 of 60 SNPs in EAS samples and 42 of 66 SNPs in AFR samples; the strongest concordance with SAS samples may not be surprising because South Asians are more closely related to Europeans than are East Asians or Africans. Moreover, strong correlation of effect sizes was observed for EUR samples with SAS, EAS and AFR samples (r = 0.55, 0.60 and 0.48, respectively). SBP and DBP risk scores composed of 66 SNPs were significant predictors of SBP and DBP, respectively, in all samples. SBP and DBP risk scores that were 1 mm Hg higher in EUR samples were associated with increases of 0.58 and 0.50 mm Hg in SBP and DBP, respectively, in SAS samples (SBP P = 1.5 × 10 −19 , DBP P = 3.2 × 10 −15 ), increases of 0.49 and 0.50 mm Hg in SBP and DBP in EAS samples (SBP P = 1.9 × 10 −10 , DBP P = 1.3 × 10 −7 ), and increases of 0.51 and 0.47 mm Hg in SBP and DBP in AFR samples (SBP P = 2.2 × 10 −21 , DBP P = 6.5 × 10 −19 ). The attenuation of the genetic risk score estimates in non-European ancestries is presumably due to inclusion of a subset of variants that lack association in the non-European or admixed samples.
We subsequently performed a trans-ancestry meta-analysis of the 66 SNPs in all 64,421 samples from the three non-European ancestry groups. After correcting for 66 tests, 12 of the 66 SNPs were significantly associated with either SBP or DBP (P < 7.6 × 10 −4 ), with correlation between EUR and non-EUR effect estimates of 0.77 for SBP Shown are the estimated effects of a blood pressure risk score comprising up to 66 SNPs (actual number given in "Total SNPs" column) on risk of dichotomous outcome or increment in continuous measures per 1 mm Hg predicted from the SBP or DBP score. Effect sizes are expressed as the incremental change in the phenotype for quantitative traits and as the odds ratio for binary traits per a predicted increase of 1 mm Hg in SBP or DBP.
P values are bolded if they meet an analysis-wide significance threshold (<0.05/18 = 0.0028). Results are shown for all SNPs ("all") and for pruned SNPs ("p"). The results for pruned SNPs were obtained by iterative removal of SNPs from the risk score, starting with the SNP with the lowest heterogeneity P value (P het A r t i c l e s and 0.67 for DBP; the EUR-ancestry SBP and DBP risk scores were associated with increases of 0.53 and 0.48 mm Hg in blood pressure per 1 mm Hg of predicted SBP and DBP, respectively (SBP P < 6.6 × 10 −48 , DBP P < 1.3 × 10 −38 ). For 7 of the 12 significant SNPs, no association has previously been reported in genome-wide studies of non-European ancestry. Some heterogeneity was observed between EUR and non-EUR effect estimates ( Supplementary Table 24 ). Taken together, these findings suggest that, in aggregate, blood pressure loci identified using data from individuals of EUR ancestry are also predictive of blood pressure in non-EUR samples, but larger non-EUR sample sizes will be needed to establish precisely which individual SNPs are associated in a given ancestry group.
Impact on hypertensive target organ damage
Long-term elevated blood pressure causes target organ damage, especially in the heart, kidney, brain, large blood vessels and retinal vessels 37 . Consequently, the genetic effect of the 66 SBP-and DBPassociated SNPs on end organ outcome can be tested directly using the risk score, although some outcomes lacked results for a small number of SNPs. Interestingly, blood pressure risk scores significantly predicted (Supplementary Note) coronary artery disease risk, left ventricular mass and wall thickness, stroke, urinary albumin/creatinine ratio, carotid intimamedial thickness and central retinal artery caliber, but not heart failure or other kidney phenotypes, after accounting for the number of outcomes examined ( Table 3) . Because outlier effects can influence risk scores, potentially due to pleiotropic effects, we repeated the risk score analysis while iteratively removing SNPs that contributed to statistical heterogeneity (SNP-trait effects relative to SNP-blood pressure effects). Heterogeneity was defined on the basis of a multiple-testing-adjusted significance threshold for Cochran's Q test of homogeneity of effects (Supplementary Note). The risk score analyses restricted to the subset of SNPs showing no heterogeneity of effect gave essentially identical results, with the exception that the urinary albumin/creatinine ratio was no longer significant. The results for each SNP are presented in Supplementary Figure 10 and Supplementary Table 25 . Because large-scale GWAS of non-blood pressure cardiovascular risk factors are available, we examined the blood pressure risk scores as predictors of other cardiovascular risk factors: LDL cholesterol, HDL cholesterol, triglycerides, type 2 diabetes, BMI and height. We observed nominal (P < 0.05) association of the blood pressure risk scores with these risk factors, although the effects were mostly in the opposite direction to the risk factor-cardiovascular disease association ( Supplementary Table 26 ). The inability to demonstrate an effect of blood pressure risk scores on heart failure may reflect limited power from a modest sample size, but the lack of significant effects on renal measures despite adequate sample size suggests that the epidemiological relationship of higher blood pressure and worse renal function may not reflect direct consequences of blood pressure elevation.
DISCUSSION
The study reported here is the largest thus far to investigate the genomics of blood pressure in multiple continental ancestry groups. Our results highlight four major features of between-individual variation in blood pressure: (i) we identified 66 (17 new) genome-wide significant loci for SBP and DBP by targeted genotyping in up to 342,415 individuals of EUR ancestry that cumulatively explain ~3.5% of the trait; (ii) the variants were enriched for cis-regulatory elements, particularly in vascular endothelial cells; (iii) the variants had broadly comparable effects on blood pressure in South Asians, East Asians and Africans, albeit in smaller sample sizes; and (iv) a 66-SNP risk score predicted target organ damage in the heart, cerebral vessels, carotid artery and eye with little evidence for an effect in the kidney.
Overall, there was no enrichment of a single genetic pathway in our data; rather, our results are consistent with the effects of blood pressure arising from multiple tissues and organs. Genetic and molecular analyses of Mendelian syndromes of HTN and hypotension point largely to a renal origin, involving multiple rare deleterious mutations of proteins that regulate salt-water balance 38 . This is strong support for Guyton's hypothesis that the regulation of sodium excretion by the kidney and its effects on extracellular volume are a prime pathway determining intra-arterial pressure 39 . However, our genetic data from unselected individuals in the general community argue against a single, dominant renal effect. The 66 SNPs we identified are not chance effects but have a global distribution and impact on blood pressure that are consistent as measured by their effects across the many studies on which meta-analysis was performed. That these sites are polymorphic across all continental ancestry groups argues for their origin and functional effects before human continental differentiation.
However, several of the 17 new loci contain strong positional biological candidates; these are described in greater detail in Supplementary  Table 27 and the Supplementary Note. The single most common feature we identified was the enrichment of regulatory elements for gene expression in vascular endothelial cells. The broad distribution of these cells across both large and small vessels and across all tissues and organs suggests that functional variation in these cells affects endothelial permeability or vascular smooth muscle cell contractility via multiple pathways. These hypotheses will need to be tested rigorously in appropriate models, to assess the contribution of these pathways to blood pressure control, and these pathways could also be targets for systemic antihypertensive therapy as they are for the pulmonary circulation 40 .
In summary, these genetic observations may contribute to an improved understanding of blood pressure biology and a reevaluation of the pathways considered relevant for therapeutic blood pressure control. 
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ONLINE METhODS
Cohorts contributing to systolic and diastolic blood pressure analyses. Studies contributing to blood pressure association discovery, including community-and population-based collections as well as studies of non-blood pressure traits, were analyzed as case and control samples separately. Details on each of the studies, including study design and blood pressure measurement, are provided in Supplementary Table 1 , genotyping information appears in Supplementary Table 2 and participant characteristics are given in Supplementary Table 3 . All participants provided written informed consent, and the studies were approved by local research ethics committees and/or institutional review boards.
European-ancestry meta-analysis. Blood pressure was measured using standardized protocols in all studies regardless of whether the primary focus was blood pressure or another trait. We initially analyzed affected and unaffected individuals from samples selected as cases (for example, type 2 diabetes) or controls separately. However, because sensitivity analyses did not show any significant difference in blood pressure effect size estimates between case and control samples (data not shown), we analyzed all samples together. When available, the average of two blood pressure measurements was used for association analyses ( Supplementary Table 1 ). If an individual was taking a blood pressure-lowering treatment, the underlying SBP and DBP were estimated by adding 15 mm Hg and 10 mm Hg, respectively, to the measured values, as done in previous analyses.
A meta-analysis of 340,934 individuals of EUR descent was undertaken in four stages with subsequent validation in an independent cohort. Because stage 1 Cardio-MetaboChip samples included many SNPs selected on the basis of association with blood pressure in earlier GWAS, we performed genomic control using a set of putative null SNPs selected on the basis of P > 0.10 in earlier GWAS of SBP and DBP, or both. Stage 2 samples with genome-wide genotyping used the entire genome-wide set of SNPs for genomic control, given the lack of ascertainment. The study design is summarized in Supplementary  Figure 1 , and further details are provided in Supplementary Tables 2-5 and the Supplementary Note. Systematic PubMed search of the region ±100 kb with respect to each newly discovered index SNP. All genes with any overlap with a 200-kb region centered on each of the 17 newly discovered lead SNPs were identified using the UCSC Genome Browser. A search term was constructed for each gene including the short and long gene names and the terms "blood pressure" and "hypertension" (for example, for NPPA on chromosome 1: "NPPA OR natriuretic peptide A AND (blood pressure OR hypertension)"), and the search results for each search term from PubMed were individually reviewed.
Trait variance explained. The trait variance explained by 66 lead SNPs at new and known loci was evaluated in one study that contributed to the discovery effort: the Atherosclerosis Risk in Communities (ARIC) study. We constructed a linear regression model with all 66 SNPs or the subset of 49 known SNPs as a set of predictors of the blood pressure residual after adjustment for covariates of the adjusted treatment-corrected blood pressure phenotype (SBP or DBP). The r 2 value from the regression model was used as the estimate of trait variance explained.
European-ancestry GCTA-COJO analysis.
To identify multiple distinct association signals at any given blood pressure locus, we undertook approximate conditional analyses using a model selection procedure implemented in the GCTA-COJO software package 22, 23 . To evaluate the robustness of the GCTA-COJO results to the choice of reference data set, model selection was performed using the LD between variants in separate analyses from two data sets of EUR descent, both with individuals from the UK with Cardio-MetaboChip genotype data: GoDARTS with 7,006 individuals and WTCCC1-T2D/58BC with 2,947 individuals. Assuming that the LD between SNPs separated by more than 10 Mb or on different chromosomes is zero, we undertook GCTA-COJO stepwise model selection to select SNPs that were conditionally independently associated with SBP and DBP, in turn, at genome-wide significance given by P < 5 × 10 −8 (Supplementary Tables 6-8 ) using the stage 4 combined EUR GWAS + Cardio-MetaboChip meta-analysis data.
Conditional analyses in the Women's Genome Health Study. Multivariate regression modeling was performed for each possible combination of putative independent SNPs from (i) model selection implemented in GCTA-COJO and (ii) a comprehensive manual review of the literature ( Supplementary Table 9 ). Any SNP with P < 5 × 10 −8 in a previously reported blood pressure GWAS was considered. A total of 46 SNPs were examined ( Supplementary Table 10 ). Genome-wide genotyping data imputed to 1000 Genomes Project in the WGHS (n = 23,047) were used. Regression modeling was performed in the R statistical language ( Supplementary Table 10 ).
Fine-mapping and determination of credible sets of causal SNPs. The GCTA-COJO and WGHS conditional analyses identified multiple distinct signals of association at multiple loci (Supplementary Tables 6 and 10) . Of the 24 loci considered in fine-mapping analyses, 16 had no evidence for the existence of multiple distinct association signals, so it is reasonable to assume that there is a single causal SNP and, therefore, the credible sets of variants could be constructed using the association summary statistics from the unconditioned meta-analyses. However, in the remaining eight loci, where evidence of secondary signals was observed from GCTA-COJO, we performed approximate conditional analyses across the region by conditioning on each index SNP ( Supplementary Table 11 ). By adjusting for the other index SNPs at the locus, we can therefore assume that a single variant is driving each conditionally independent association signal and can construct the 99% credible set of variants on the basis of the approximate conditional analysis from GCTA-COJO ( Supplementary Tables 12 and 13) . At five of the eight loci with multiple distinct signals of association, one index SNP mapped outside the fine-mapping region, so a credible set could not be constructed. eQTL analysis: whole blood. Whole-blood expression quantitative trait locus (eQTL) analyses were performed in samples from the Netherlands Study of Depression and Anxiety (NESDA) 41 and the Netherlands Twin Registry (NTR) 42 studies. RNA expression analysis was performed using statistical software R. The residuals resulting from linear regression analysis of the probe set intensity values onto the covariates sex, age, BMI (kg/m 2 ), smoking status coded as a categorical covariate, several technical covariates and three principal components were used. eQTL effects were detected using a linear mixed-model approach, including for each probe set the expression level (normalized, residualized and without the first 50 expression principal components) as dependent variable; the SNP genotype values as fixed effects; and family identifier and zygosity (in the case of twins) as random effects to account for family and twin relationships 43 .
The eQTL effects were defined as being in cis when probe set-SNP pairs were separated by a distance of <1 Mb. At an FDR of 0.01 applied across the genome, not just for candidate SNPs, the P-value threshold was 1 × 10 −4 for the cis-eQTL analysis. For each probe set that displayed a statistically significant association with at least one SNP located within its cis region, we identified the most significantly associated SNP and denoted this as the top cis-eQTL SNP. See the Supplementary Note for details. eQTL analysis: selected published eQTL data sets. Lead blood pressure SNPs and proxies (r 2 >0.8) were searched against a collected database of eSNP results. The reported eSNP results met criteria for statistical thresholds for association with gene transcript levels as described in the original papers. The non-blood-cell tissue eQTLs searched included aortic endothelial cells 44 , left ventricle of the heart 45 , CD14 + monocytes 46 and brain 47 . The results are presented in Supplementary Tables 14 and 15. Enrichment analyses: analysis of cell-type-specific DHSs using an odds ratio method. The overlap of Cardio-MetaboChip SNPs with DHSs was examined using publicly available data from the Epigenomics Roadmap Project and ENCODE, choosing different cutoffs of Cardio-MetaboChip P value. DHS mappings were available for 123 cell types and tissues mostly derived from adults 29 . The DHS mappings were specified as both 'narrow' and 'broad' peaks, referring to reduction of the experimental data to peak calls at 0.1% and 1.0% FDR thresholds, respectively. Thus, the narrow peaks are largely nested within the broad peaks. Experimental replicates of the DHS mappings (typically duplicates) were also available for the majority of cell types and tissues.
